Download MendeleyFragment-based discovery of hepatitis C virus NS5b RNA polymerase inhibitors.
Antonysamy, S.S., Aubol, B., Blaney, J., Browner, M.F., Giannetti, A.M., Harris, S.F., Hebert, N., Hendle, J., Hopkins, S., Jefferson, E., Kissinger, C., Leveque, V., Marciano, D., McGee, E., Najera, I., Nolan, B., Tomimoto, M., Torres, E., Wright, T.(2008) Bioorg Med Chem Lett 18: 2990-2995
- PubMed: 18400495
- DOI: https://doi.org/10.1016/j.bmcl.2008.03.056
- Primary Citation of Related Structures:
3CIZ, 3CJ0, 3CJ2, 3CJ3, 3CJ4, 3CJ5 - PubMed Abstract:
Non-nucleoside inhibitors of HCV NS5b RNA polymerase were discovered by a fragment-based lead discovery approach, beginning with crystallographic fragment screening. The NS5b binding affinity and biochemical activity of fragment hits and inhibitors was determined by surface plasmon resonance (Biacore) and an enzyme inhibition assay, respectively. Crystallographic fragment screening hits with approximately 1-10mM binding affinity (K(D)) were iteratively optimized to give leads with approximately 200nM biochemical activity and low microM cellular activity in a Replicon assay.
Organizational Affiliation:
Medicinal Chemistry, SGX Pharmaceuticals, Inc., 10505 Roselle Street, San Diego, CA 92121, USA.
